Alaris Equity Partners today reported its financial results for the three and nine months ended 30, 2025, highlighting continued strength across its Partner portfolio and steady cash flow generation.

Greetings. Welcome to Kingstone Companies' Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. Joining us on today's call will be ...

Background To assess subfoveal choroidal thickness (SFCT) and its associations in school children in a Russian population. Methods The Ural Children Eye Study (UCES), a school-based case-control study ...

The U.S. Food & Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS® (zongertinib tablets), currently under investigation for first-line use in ...

Canadian Tire Corporation, Limited (TSX: CTC) (TSX: CTC.A) (CTC or the Company) today announced results for its third quarter ...

Objectives Neurogranin (Ng) has a role in synaptic plasticity and is considered a biomarker of synaptic dysfunction, a process hypothesised to be important in delirium. Few studies examining Ng in ...

Background Postoperative ileus (POI) is a common complication after abdominal surgery that significantly delays recovery. Evidence suggests that the general anaesthetic propofol inhibits ...

THIRD QUARTER FINANCIAL RESULTS "Our portfolio of high-quality assets continued to deliver strong results, generating record revenue, earnings, and cash flow for the first nine months of 2025," said ...